Pyxis Oncology (NASDAQ:PYXS) is down ~38% in after-hours trading Wednesday after posting preliminary phase 1 data on PYX-201, an antibody-drug conjugate for solid tumors. The data presented was in six ...

Any time a business conference producer approaches the day when all the speakers and attendees get on airplanes and fly to the venue, things change fast. A speaker cancels and has to be replaced at ...

Having recently trimmed back its pipeline to a sole cancer candidate, Pyxis Oncology has now reduced its head count to match. The Boston biotech is shrinking its workforce by "approximately" 20%, it ...

As the U.S. stock market experiences mixed performances, with tech stocks showing resilience amid a backdrop of economic uncertainty, investors are increasingly exploring diverse opportunities. Penny ...

Apexigen’s rapid decline is nearly complete. Three years after its private megaround, and less than 300 days after going public, the biotech has accepted a $16 million buyout bid from Pyxis Oncology.

Pyxis Oncology, Inc. (PYXS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in ...

Every company I speak with is building mobile software for its customers (B2C) or its employees (B2E). In effect, the entire software market is morphng before our eyes as the world deals with enabling ...

It’s been a good week for investors of Pyxis Oncology (NASDAQ:PYXS), to say the least. Over the past 4 sessions Pyxis shares have gained 170%, bringing the year-to-date haul to a mighty 340%. This ...